07:21 AM EDT, 03/25/2025 (MT Newswires) -- Mural Oncology ( MURA ) said Tuesday that it will stop development of nemvaleukin alfa for platinum-resistant ovarian cancer as it believes a phase 3 trial of the drug combined with Merck's ( MRK ) Keytruda is "highly unlikely to achieve success" at the final analysis.

The company said the independent data monitoring committee's interim analysis showed no statistically significant improvement in overall survival compared with chemotherapy alone.

Median overall survival was 10.1 months for patients treated with the experimental combination therapy versus 9.8 months for those who received chemotherapy, according to the company.

Mural said nemvaleukin is still being assessed in a phase 2 trial for mucosal melanoma, with topline data expected in Q2.

Shares of Mural fell 41% in recent premarket activity.